Catalogo dei prodotti della ricerca

IACOVELLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.574
EU - Europa 2.662
AS - Asia 540
SA - Sud America 42
AF - Africa 36
OC - Oceania 3
Totale 6.857
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.550
IT - Italia 2.087
SG - Singapore 217
IN - India 160
CN - Cina 143
SE - Svezia 130
DE - Germania 102
FI - Finlandia 97
RU - Federazione Russa 72
UA - Ucraina 67
TG - Togo 28
BR - Brasile 24
GB - Regno Unito 24
CA - Canada 23
IE - Irlanda 18
FR - Francia 17
AR - Argentina 15
RO - Romania 10
BG - Bulgaria 8
BE - Belgio 7
NL - Olanda 6
PL - Polonia 5
CH - Svizzera 4
ID - Indonesia 4
TR - Turchia 4
ZA - Sudafrica 3
AU - Australia 2
BD - Bangladesh 2
ES - Italia 2
HK - Hong Kong 2
SC - Seychelles 2
UZ - Uzbekistan 2
AM - Armenia 1
BY - Bielorussia 1
CL - Cile 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
KR - Corea 1
LT - Lituania 1
LU - Lussemburgo 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
RS - Serbia 1
VE - Venezuela 1
VN - Vietnam 1
Totale 6.857
Salva come PNG Salva come JPEG
Città #
Fairfield 683
Woodbridge 281
Ashburn 280
Rome 265
Seattle 240
Houston 219
Chandler 207
Wilmington 204
Cambridge 187
Singapore 129
Ann Arbor 120
Santa Clara 111
Beijing 107
Princeton 87
Plano 77
Lawrence 67
Boston 59
San Paolo di Civitate 47
Dearborn 42
Milan 42
San Diego 42
Napoli 37
Munich 35
Andover 28
Lomé 28
Millbury 27
Jacksonville 24
Palermo 24
Helsinki 20
Catania 17
Dublin 15
Federal 15
Moscow 15
Bari 13
Fremont 13
Toronto 13
Turin 12
Des Moines 11
New York 11
Bühl 10
Naples 10
Norwalk 10
Ottawa 9
Bologna 8
Cagliari 8
Florence 8
Sofia 8
Yubileyny 8
Boardman 7
Brussels 7
Civitavecchia 7
Falkenstein 7
London 7
Padova 7
Redmond 7
Caserta 6
Latina 6
San Mateo 6
Sesto Fiorentino 6
Falls Church 5
Hefei 5
Livorno 5
Marigliano 5
Navacchio 5
Pune 5
Reggio Calabria 5
Seregno 5
São Paulo 5
Avellino 4
Bacoli 4
Castellammare Di Stabia 4
Como 4
Council Bluffs 4
Dallas 4
Floriano 4
Giugliano In Campania 4
Grafing 4
Jakarta 4
Mannheim 4
Martina Franca 4
Messina 4
Redwood City 4
Siracusa 4
Taranto 4
Alghero 3
Bern 3
Caivano 3
Eboli 3
Erice 3
Foggia 3
Grottaglie 3
Jinan 3
Kayseri 3
Kunming 3
Lissone 3
Los Angeles 3
Nanjing 3
Nardò 3
Ningbo 3
Perugia 3
Totale 4.163
Salva come PNG Salva come JPEG
Nome #
Efficacia terapeutica del Ninfagin ovuli nelle flogosi aspecifiche cervico-vaginali 1.983
Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature 93
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 92
Neo-adjuvant and adjuvant chemotherapy in bladder cancer. 91
Gemcitabine-induced extensive skin necrosis 90
Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules 89
Abiraterone acetate in castration-resistant prostate cancer 87
Antiangiogenic agents are ineffective to increase complete response rate in MRCC:A meta-analysis 86
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. 86
Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib 86
Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney 82
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma 82
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. 81
Clinical and pathological features of primary renal angiosarcoma. 79
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials 78
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy 77
Adverse events related to abiraterone and enzalutamide treatment. analysis of the EudraVigilance database and meta-analysis of registrational phase III studies 77
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma 76
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies 75
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. 75
Past, Present and Future of Targeted Therapy in Solid Tumors 73
Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma 73
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. 72
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. 71
Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature. 68
Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. 67
Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. 67
Molecular markers in circulating tumour cells from metastatic colorectal cancer patients 66
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 66
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort 65
Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. 64
Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. 63
Targeted treatments in advanced renal cell carcinoma: focus on axitinib. 63
null 63
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. 63
Renal cell carcinoma: incidence and cost estimation in the era of targeted therapy. 63
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. 63
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials 62
Reply to"mTOR inhibitor-related pulmonary toxicity;incidence even higher" 60
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. 60
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. 60
Neoadjuvant targeted therapy in renal cell carcinoma 60
Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies 59
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. 59
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. 58
Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. 58
Erlotinib in metastatic non-small cell lung cancer (NSCLC) patients unselected for Epidermal Growth Factor Receptors (EGFR) mutations: a retrospective analysis of elderly patients 58
Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. 57
Role of MGMT as biomarker in colorectal cancer. 57
FOLFIRI with cetuximab or bevacizumab: FIRE-3. 56
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma 56
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. 55
Salvage therapy for recurrence of bladder cancer: do we need a uniform approach? 54
null 54
Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? 53
Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program 53
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. 53
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer. A systematic review and meta-analysis. 52
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases 52
Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer. 52
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: A retrospective Italian survey 51
The End of Chemotherapy in Renal Cell Carcinoma: For Much But Not for All 51
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies 51
Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum 48
Clear cell carcinoma of the urinary bladder. A case report: surgical and oncological managemet 47
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma. 46
Adverse events related to radium-223 treatment: "real-life" data from the Eudra-Vigilance database 46
Umbilical node as first clinical appearance in a patient with a high tumor burden. 43
Prevalence of acetowhite areas in male parteners of women affected by HPV and squamous intraepithelial lesions (SIL) and their prognostic significance. A multicentre study 42
Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. Analysis of risk factors 40
Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. 40
PEMETREXED-RELATED RENAL TOXICITY IN PATIENTS (PTS) WITH THORACIC MALIGNANCIES 39
Treatment of collecting duct carcinoma: current status and future perspectives. 39
Left ventricular ejection fraction drop at 12 weeks in elderly breast cancer patients treated with transtuzumab is meaningful for a further unrecovered cardiotoxicity 37
Verrucous carcinoma of the cervix: Detection of carcinogenetic human papillomavirus types and their role during follow-up 36
Incidence and risk of pulmonary toxicity in patients treated with mTOR ihibitors for malignancy. A meta-analysis of published trials 35
Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma. 34
null 33
Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program 31
Study design and clinical evidence in mRCC: Can we save axitinib as a first-line therapy? 31
null 23
First line treatment of metastatic renal cell carcinoma Two standards with different toxicity profile 22
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations. Differential Effectiveness by Risk Group? 21
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. 18
Regression rate of clinical HPV infection of the lower genital tract during pregnancy after laser CO2 surgery 17
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. 17
Navigating the rapidly evolving advanced urothelial carcinoma treatment landscape: insights from italian experts 13
Correction to: Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis (Targeted Oncology, (2020), 15, 4, (495-501), 10.1007/s11523-020-00732-y) 12
null 11
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. 5
Totale 6.972
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.964
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.964
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020422 0 0 0 0 0 0 0 0 146 147 67 62
2020/2021467 44 73 14 40 39 45 12 59 65 34 29 13
2021/2022908 11 70 107 18 119 19 26 105 63 88 105 177
2022/2023945 169 223 43 83 94 89 18 51 97 16 40 22
2023/2024414 28 55 23 17 43 49 3 27 6 83 46 34
2024/2025475 26 29 61 17 139 59 87 44 13 0 0 0
Totale 6.972